All titles, abstracts, photos and YouTube presentations will need your research mentor’s approval prior to submitting your abstract. The abstract will be open to public viewing. Submit your abstract ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that more than 40 abstracts highlighting data from eight of its hematology and oncology products will be presented at the ...

CAMBRIDGE, Mass. & MONTREAL, April 25, 2025--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced ...

NANTES, France – April 23, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral ...

Work can be submitted to one of the five categories. Abstracts that do not contain data may be accepted for an online recording on VoiceThread but will not qualify for an in-person presentation or ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of four posters ...

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced that abstracts for multiple presentations have been accepted for the 2025 National Summit of the US Hereditary Angioedema ...

This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to ...

INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in ...

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature the full ...